The appointment of Dr. Egeler is an important milestone in the development of Kiadis Pharma's lead product ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients. Dr. Egeler's appointment will strongly support the upcoming multi-center pivotal study on ATIR(TM) early 2009.
Dr. Egeler will join Kiadis Pharma part time next to his position as Head of the Pediatric Oncology and Bone Marrow Transplantation division of the University of Leiden. As Kiadis Pharma's CMO, he will oversee all medical affairs of the company and he will work closely with the company's global network of key opinion leaders in the transplantation community on the development of the company's products.
"Maarten has been acting as a medical advisor for Kiadis Pharma over the
last year and we are very pleased that he agreed to become our CMO", says
"I am very excited to join Kiadis Pharma in the role of CMO. I look
forward to participate in the development of its programs. I am particularly
excited to work on the ATIR(TM) product, which is aimed at preventing acute
Graft versus Host Disease and thus enables severe mismatched bone marrow
transplantation (so-called 'haplo-identical transplantation') and is entering
a pivotal study in early 2009", says
For the complete press release please go to: http://www.kiadis.com/news For more information please contact: Kiadis Pharma B.V. Eefje Simpelaar Director Communications Email: email@example.com Tel: +31-20-3140250 Mob: +31-6-10829344
SOURCE Kiadis Pharma